SMARCA4 and non-small cell lung carcinoma: The results of the Cox-regression multivariate analysis demonstrated that KRAS/SMARCA4 class 1 co-mutations are associated with worse OS compared to KRAS mutations for patients with NSCLC (HR = 3.23; 95% CI: 1.90–5.51; p < 0.001).